STAT3 inhibitor WP1066 attenuates miRNA-21 to suppress human oral squamous cell carcinoma growth in vitro and in vivo

Oncology Reports

Volumn 31, Issue 5, 2014, Pages 2173-2180

  Zhou, Xuan ^a,b   Ren, Yu ^a   Liu, Aiqin ^a   Han, Lei ^a   Zhang, Kailiang ^a   Li, Shasha ^a   Li, Peng ^c   Li, Ping ^a   Kang, Chunsheng ^a   Wang, Xudong ^b   Zhang, Lun ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^c Tianjin Medical College   (China)

Author keywords

Interleukin 6; MiRNA 21; Oral squamous cell carcinoma; Signal transducer and activator of transcription 3; WP1066

Indexed keywords

ANTINEOPLASTIC AGENT; GELATINASE A; INTERLEUKIN 6; KI 67 ANTIGEN; MEMBRANE PROTEIN; MICRORNA 21; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGRAMMED CELL DEATH 4; PROTEIN BCL 2; STAT3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG; WP 1066; 3 (6 BROMO 2 PYRIDINYL) 2 CYANO N (1 PHENYLETHYL)ACRYLAMIDE; APOPTOSIS REGULATORY PROTEIN; IL6 PROTEIN, HUMAN; MICRORNA; MIRN21 MICRORNA, HUMAN; PDCD4 PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; PYRIDINE DERIVATIVE; RNA BINDING PROTEIN; STAT3 PROTEIN, HUMAN; TIMP3 PROTEIN, HUMAN; TYRPHOSTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL GROWTH; CELL MIGRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; METABOLISM; MOUSE; MOUTH NEOPLASMS; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INTERLEUKIN-6; KI-67 ANTIGEN; MATRIX METALLOPROTEINASE 2; MICE; MICE, NUDE; MICRORNAS; MOUTH NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; PTEN PHOSPHOHYDROLASE; PYRIDINES; RNA-BINDING PROTEINS; STAT3 TRANSCRIPTION FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TYRPHOSTINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84898638447     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3114     Document Type: Article

References (33)

1. Posner M and Vermorken JB: Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer. Semin Oncol 35: 221-228, 2008
2. Cohen EE, Lingen MW and Vokes EE: The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 9: 1743-1752, 2004
3. He L and Hannon GJ: MicroRNAs: Small RNAs with a big roll in gene regulation. Nat Rev Genet 5: 522-531, 2004
4. Pan X, Wang ZX and Wang R: MicroRNA-21: A novel therapeutic target in human cancer. Cancer Biol Ther 12: 1224-1232, 2010
5. Gaur AB, Holbeck SL, Colburn NH and Israel MA: Down-regulation of Pdcd4 by mir-21 facilitates glioblastoma pro-liferation in vivo. Neuro Oncol 13: 580-590, 2011
6. Meng F, Henson R, Wehbe-Janek H, et al: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133: 647-658, 2007
7. Gabriely G, Wurdinger T, Kesari S, et al: MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol 28: 5369-5380, 2008
8. Rawlings JS, Rosler KM and Harrison DA: The JAK/STAT signaling pathway. J Cell Sci 117: 1281-1283, 2004
9. He G and Karin M: NF-?B and STAT3 - key players in liver inflammation and cancer. Cell Res 21: 159-168, 2011
10. Wang YY, Sun G, Luo H, et al: MiR-21 modulates hTERT through a STAT3-dependent manner on glioblastoma cell growth. CNS Neurosci Ther 18: 722-728, 2012
11. Han L, Yue X, Zhou X, et al: MicroRNA-21 expression is regulated by ?-catenin/STAT3 pathway and promotes glioma cell invasion by direct targeting RECK. CNS Neurosci Ther 18: 573-583, 2012
12. Yang CH, Yue J, Pfeffer SR, et al: MicroRNA miR-21 regulates the metastatic behavior of B16 melanoma cells. J Biol Chem 286: 39172-39178, 2011
13. Lederle W, Depner S, Schnur S, et al: IL-6 promotes malignant growth of skin SCCs by regulating a network of autocrine and paracrine cytokines. Int J Cancer 128: 2803-2814, 2011
14. Zhou X, Ren Y, Moore L, et al: Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab Invest 90: 144-155, 2010
15. Han L, Zhang A, Wang H, et al: Tat-BMPs-PAMAM conjugates enhance therapeutic effect of small interference RNA on U251 glioma cells in vitro and in vivo. Hum Gene Ther 4: 417-426, 2010
16. Li J, Huang H, Sun L, et al: MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res 15: 3998-4008, 2009
17. Yu ZW, Zhong LP, Ji T, et al: MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 46: 317-322, 2010
18. Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005
19. Grandis JR, Drenning SD, Zeng Q, et al: Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci 97: 4227-4232, 2000
20. Bourguignon LY, Earle C, Wong G, et al: Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells. Oncogene 31: 149-160, 2012
21. Volinia S, Calin GA, Liu CG, et al: A micro-RNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261, 2006
22. Fu X, Han Y, Wu Y, et al: Prognostic role of microRNA-21 in various carcinomas: A systematic review and meta-analysis. Eur J Clin Invest 41: 1245-1253, 2011
23. Iorio MV andCroce CM: Causes and consequences of microRNA dysregulation. Cancer J 18: 215-222, 2012
24. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, et al: Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 11: 141-147, 2010
25. Löffler D, Brocke-Heidrich K, Pfeifer G, et al: Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 110: 1330-1333, 2007
26. Horiguchi A, Asano T, Kuroda K, et al: STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer 102: 1592-1599, 2010
27. Darnell JE: Validating Stat3 in cancer therapy. Nat Med 11: 595-596, 2005
28. Bromberg J: Stat proteins and oncogenesis. J Clin Invest 109: 1139-1142, 2002
29. Grandis JR, Drenning SD, Chakraborty A, et al: Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest 102: 1385-1392, 1998
30. Johnson DE: Targeting proliferation and survival pathways in head and neck cancer for therapeutic benefit. Chin J Cancer 31: 319-326, 2012
31. Agarwal E, Brattain MG and Chowdhury S: Cell survival and metastasis regulation by Akt signaling in colorectal cancer. Cell Signal 25: 1711-1719, 2013
32. Kotzsch M, Farthmann J, Meye A, et al: Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer. Eur J Cancer 41: 2760-2768, 2005
33. Göke R, Barth P, Schmidt A, et al: Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21Waf1/Cip1. Am J Physiol Cell Physiol 287: C1541-C1546, 2004